The Transcription Factor SOX18 Inhibitor Small Molecule 4 Is a Potential Treatment of Cancer‐Induced Lymphatic Metastasis and Lymphangiosarcoma
These findings suggest that targeting SOX18 with Sm4 may hold potential as a therapeutic strategy for lymphangiosarcoma and cancer-induced lymphatic metastasis. Further in vitro studies are warranted to investigate the mechanisms and conduct dose-response analyses to evaluate Sm4's potential as a targeted therapy for lymphangiosarcoma and cancer-induced lymphangiogenesis in the future.
Authors
- Patrick A. Will (ORCID: https://orcid.org/0000-0003-3430-1795)
- Ulrich Kneser (ORCID: https://orcid.org/0000-0002-3402-2860)
- Christoph Hirche (ORCID: https://orcid.org/0000-0001-6112-8671)
- M. Zimmermann
- Katja K. Koll
Institutions
- Goethe University Frankfurt (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Klinikum Ludwigshafen (DE)
- Berufsgenossenschaftliche Unfallklinik Frankfurt am Main (DE)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cnr2.70110
- Citations
- 2
- Primary Topic
- Lymphatic System and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Kitasato University